On September 22, 2018, at the Main Arena of the annual academic conference of Transcatheter Cardiovascular Therapeutics (TCT) 2018 in San Diego, California, USA, BIOSENSORS INTERNATIONAL, the parent company of JWMS, announced the results of the primary endpoint of its world-renowned LEADERS FREE II trial. This new study confirmed the reproducibility of previous good results of European LEADERS FREE trials, which could lead to wider clinical practice on HBR patients in North America